ZenagamtideFirst-in-human oral multiple-dose cohort · NCT05369390
Phase 1 · 12 weeks
144Actual registry enrollment
RandomizedSequential assignment · Treatment
QuadrupleParticipant, Care provider, Investigator, Outcomes assessor
15 trial results.
One honest chart.
Compare reported mean weight change and registered study design for Retatrutide, CagriSema, MariTide, Cagrilintide, Zenagamtide/Amycretin, Survodutide, VK2735, and other named programs. Every percentage stays attached to its weeks, phase, route, population, comparator, estimand, registry record, and outcome source.
Trial observations15Each source and method attached
Named programs13Including two VK2735 formulations
Duration range12-80Weeks, never converted to a weekly rate
Primary sources14Peer-reviewed and sponsor records
The direct answer
The biggest percentage is not automatically the best drug.
Retatrutide's 28.3% TRIUMPH-1 efficacy estimate is the highest value in this selected chart. CagriSema reported 22.7% under a different trial-product estimand, Enicepatide reported a 22.5% placebo-adjusted difference, and MariTide reported up to 19.9% across Phase 2 dose groups. Those are not matching measures from one contest.
A useful comparison starts by matching the clinical question. Check who entered the study, how long they were followed, whether the value is an active-arm mean or placebo-adjusted difference, what happened after discontinuation, and which estimand produced the number.
Cross-trial boundaryA source-linked orientation dataset of selected reported mean body-weight results from separate clinical trials. Differences in population, duration, dose, route, phase, estimand, adherence assumptions, rescue treatment, missing-data handling, comparator response, and source maturity prevent a cross-trial efficacy or safety ranking. A chart position is not a treatment recommendation, approval, individual prediction, or head-to-head result.
Interactive clinical-trial chart
Filter the evidence before comparing the percentage.
Every point remains attached to a named trial, duration, route, phase, population, statistical basis, and primary source. The chart describes separate records. It does not rank treatments.
15results shownPoint height uses the source's reported percentage, not a normalized treatment effect.
30%
25%
20%
15%
10%
5%
0%
Phase 1Phase 2Phase 3Horizontal axis: weeks. Vertical axis: source-reported mean reduction or placebo-adjusted difference.
Clinical trial design comparison
Study context before outcome size.
This matrix uses the same filters as the chart. It exposes the current ClinicalTrials.gov enrollment, allocation, intervention model, masking, study status, and the maturity of the separate outcome source. These fields describe evidence context. They do not produce a quality score or treatment ranking.
Two records, two jobsThe outcome source supplies the plotted percentage. ClinicalTrials.gov supplies the current study-design snapshot. Registry enrollment can differ from a publication's analyzed population or an earlier sponsor report.
VK2735 injectionVENTURE · NCT06068946
Phase 2 · 13 weeks
176Actual registry enrollment
RandomizedParallel assignment · Treatment
TripleParticipant, Care provider, Investigator
VK2735 oralVENTURE-Oral · NCT06828055
Phase 2 · 13 weeks
280Actual registry enrollment
RandomizedParallel assignment · Treatment
TripleParticipant, Care provider, Investigator
PetrelintideZUPREME-1 · NCT06662539
Phase 2 · 42 weeks
493Actual registry enrollment
RandomizedParallel assignment · Treatment
DoubleParticipant, Investigator
EnicepatideCT388-103 · NCT06525935
Phase 2 · 48 weeks
469Actual registry enrollment
RandomizedParallel assignment · Treatment
DoubleParticipant, Investigator
EloralintidePhase 2 obesity trial · NCT06230523
Phase 2 · 48 weeks
263Actual registry enrollment
RandomizedParallel assignment · Treatment
DoubleParticipant, Investigator
PemvidutideMOMENTUM · NCT05295875
Phase 2 · 48 weeks
391Actual registry enrollment
RandomizedParallel assignment · Treatment
DoubleParticipant, Investigator
EcnoglutideSLIMMER · NCT05813795
Phase 3 · 48 weeks
664Actual registry enrollment
RandomizedParallel assignment · Treatment
TripleParticipant, Care provider, Investigator
MazdutideGLORY-1 · NCT05607680
Phase 3 · 48 weeks
610Actual registry enrollment
RandomizedParallel assignment · Treatment
TripleParticipant, Care provider, Investigator
MariTidePhase 2 dose-ranging study · NCT05669599
Phase 2 · 52 weeks
592Actual registry enrollment
RandomizedParallel assignment · Treatment
QuadrupleParticipant, Care provider, Investigator, Outcomes assessor
MazdutideGLORY-2 · NCT06164873
Phase 3 · 60 weeks
462Actual registry enrollment
RandomizedParallel assignment · Treatment
QuadrupleParticipant, Care provider, Investigator, Outcomes assessor
CagriSemaREDEFINE 1 · NCT05567796
Phase 3 · 68 weeks
3,400Estimated registry enrollment
RandomizedParallel assignment · Treatment
QuadrupleParticipant, Care provider, Investigator, Outcomes assessor
CagrilintideREDEFINE 1 monotherapy arm · NCT05567796
Phase 3 · 68 weeks
3,400Estimated registry enrollment
RandomizedParallel assignment · Treatment
QuadrupleParticipant, Care provider, Investigator, Outcomes assessor
SurvodutideSYNCHRONIZE-1 · NCT06066515
Phase 3 · 76 weeks
726Actual registry enrollment
RandomizedParallel assignment · Treatment
QuadrupleParticipant, Care provider, Investigator, Outcomes assessor
RetatrutideTRIUMPH-1 · NCT05929066
Phase 3 · 80 weeks
2,335Actual registry enrollment
RandomizedParallel assignment · Treatment
DoubleParticipant, Investigator
Retatrutide
TRIUMPH-1 · NCT05929066
28.3%Active-arm mean80 weeks · Efficacy estimand
- Phase and route
- Phase 3 · Weekly injection
- Population
- Adults with obesity or overweight and at least one complication
- Participants
- 2,339 · Total randomized master-trial population
- Registry enrollment
- 2,335 · actual · updated June 3, 2026
- Study design
- Randomized · Parallel assignment · Double masking
- Comparator
- 2.2% mean reduction
- Alternate analysis
- 25% · Treatment-regimen estimand
- Current status
- Investigational; not FDA approved
The 28.3% and 25.0% figures answer different analysis questions inside the same trial. Neither creates a head-to-head result against another program.
Two-drug comparison builder
Choose two results. Diagnose the comparison.
Select any two source records to see what actually matches, what differs, and whether the evidence shares randomization. The diagnostic never calculates a winner, a weekly rate, or an invented comparability score.
Two evidence records, no shared randomization.
No participant in the cited sources was randomized between CagriSema and Retatrutide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
Active-arm mean at 80 weeks
- Trial
- TRIUMPH-1 · NCT05929066
- Estimand
- Efficacy estimand
- Participants
- 2,339 · Total randomized master-trial population
- Comparator
- 2.2% mean reduction
Active-arm mean at 68 weeks
- Trial
- REDEFINE 1 · NCT05567796
- Estimand
- Trial-product estimand
- Participants
- 3,417 · Total randomized trial population across four arms
- Comparator
- 2.3% mean reduction
Randomization recordTRIUMPH-1 · NCT05929066REDEFINE 1 · NCT05567796Separate trials
Reported measure28.3% · Active-arm mean22.7% · Active-arm meanMatching basis label; estimands may still differ
Duration80 weeks68 weeks12-week difference
Development phasePhase 3Phase 3Matching phase label
Diabetes contextWithout diabetesWithout type 2 diabetesBroad diabetes context matches
Route and scheduleWeekly injectionWeekly injectionMatching route label
Study maskingDouble · Parallel assignmentQuadruple · Parallel assignmentDifferent design context
Outcome source maturitySponsor topline report · May 21, 2026Peer-reviewed publication · June 22, 2025Read peer review and sponsor reporting separately
Crawlable result ledger
Every visible point, with its comparison limits.
The table is the durable record behind the chart. It preserves active-arm means, placebo-adjusted differences, and alternate estimands as different fields.
| Program | Trial | Weeks | Reported result | Basis and estimand | Population | Source |
|---|---|---|---|---|---|---|
| ZenagamtideAmycretin · NNC0487-0111 | First-in-human oral multiple-dose cohortPhase 1 · NCT05369390 · Completed · Daily oral | 12weeks | 13.1%Comparator: 1.1% mean reduction | Active-arm meanSponsor-reported exploratory Phase 1 mean | Adults with obesity or overweight16 participants · Active oral cohort only | Novo NordiskSponsor presentation · March 2024 |
| VK2735 injectionViking VK2735 · VENTURE injectable | VENTUREPhase 2 · NCT06068946 · Completed · Weekly injection | 13weeks | 14.7%Comparator: 1.7% mean reduction | Active-arm meanPeer-reviewed 13-week mean | Adults with obesity or overweight and at least one complication176 participants · Total randomized trial population | PubMed / ObesityPeer-reviewed publication · January 8, 2026 |
| VK2735 oralOral VK2735 · VENTURE-Oral | VENTURE-OralPhase 2 · NCT06828055 · Completed · Daily oral | 13weeks | 12.2%Comparator: 1.3% mean reduction | Active-arm meanSponsor-reported 13-week mean | Adults with obesity or overweight and at least one complication280 participants · Total randomized trial population | Viking TherapeuticsSponsor topline report · May 12, 2026 |
| PetrelintideZP8396 · long-acting amylin analogue | ZUPREME-1Phase 2 · NCT06662539 · Completed · Weekly injection | 42weeks | 10.7%Comparator: 1.7% mean reduction | Active-arm meanEfficacy estimand, upper end of five dose-group estimates | Adults with obesity or overweight and weight-related complications493 participants · Total randomized trial population | RocheSponsor topline report · March 5, 2026 |
| EnicepatideCT-388 · RO7795068 · RG6640 | CT388-103Phase 2 · NCT06525935 · Completed · Weekly injection | 48weeks | 22.5%Comparator: Not separately reported | Placebo-adjusted differencePlacebo-adjusted efficacy estimate | Adults with obesity or overweight and at least one complication469 participants · Total randomized dose-finding trial population | RocheSponsor topline report · January 27, 2026 |
| EloralintideLY3841136 · selective amylin receptor agonist | Phase 2 obesity trialPhase 2 · NCT06230523 · Completed · Weekly injection | 48weeks | 20%Comparator: 0.4% mean reduction | Active-arm meanEfficacy estimand, rounded result for two dose strategies | Adults with obesity or overweight and at least one complication263 participants · Total randomized trial population | PubMed / The LancetPeer-reviewed publication · November 7, 2025 |
| PemvidutideALT-801 · balanced GLP-1/glucagon dual agonist | MOMENTUMPhase 2 · NCT05295875 · Completed · Weekly injection | 48weeks | 15.6%Comparator: 2.2% mean reduction | Active-arm meanSponsor-reported 48-week mean | Adults with obesity, or overweight plus a comorbidity391 participants · Total randomized trial population | AltimmuneSponsor topline report · June 23, 2024 |
| EcnoglutideXW003 · Sciwind ecnoglutide · 埃诺格鲁肽 | SLIMMERPhase 3 · NCT05813795 · Completed · Weekly injection | 48weeks | 15.4%Comparator: 0.3% mean reduction | Active-arm meanTreatment-policy estimand | Chinese adults with obesity or overweight664 participants · Total randomized trial population | Sciwind BiosciencesSponsor topline report · March 6, 2026 |
| MazdutideIBI362 · LY3305677 | GLORY-1Phase 3 · NCT05607680 · Completed · Weekly injection | 48weeks | 14.01%Comparator: 0.3% mean gain | Active-arm meanPeer-reviewed trial mean | Chinese adults with obesity or overweight610 participants · Total randomized trial population | New England Journal of MedicinePeer-reviewed publication · May 28, 2025 |
| MariTidemaridebart cafraglutide · AMG 133 | Phase 2 dose-ranging studyPhase 2 · NCT05669599 · Completed · Monthly injection | 52weeks | 19.9%Comparator: 2.6% mean reduction | Active-arm meanEfficacy estimand, upper end of the reported dose-group range | Adults with obesity or overweight, without type 2 diabetes465 participants · Cohort A; 592 adults were enrolled across cohorts A and B | AmgenSponsor topline report · June 23, 2025 |
| MazdutideIBI362 · LY3305677 | GLORY-2Phase 3 · NCT06164873 · Active, not recruiting · Weekly injection | 60weeks | 16.65%Comparator: 1.5% mean reduction | Active-arm meanPeer-reviewed analysis of participants receiving at least one dose | Chinese adults with moderate to severe obesity, with or without type 2 diabetes461 participants · Participants receiving at least one dose; the registry records 462 randomized participants | PubMed / JAMAPeer-reviewed publication · June 8, 2026 |
| CagriSemacagrilintide plus semaglutide · REDEFINE 1 | REDEFINE 1Phase 3 · NCT05567796 · Active, not recruiting · Weekly injection | 68weeks | 22.7%Comparator: 2.3% mean reduction | Active-arm meanTrial-product estimand | Adults with obesity or overweight and at least one complication3,417 participants · Total randomized trial population across four arms | PubMed / New England Journal of MedicinePeer-reviewed publication · June 22, 2025 |
| CagrilintideAM833 · NNC0174-0833 | REDEFINE 1 monotherapy armPhase 3 · NCT05567796 · Active, not recruiting · Weekly injection | 68weeks | 11.8%Comparator: 2.3% mean reduction | Active-arm meanTrial-product estimand | Adults with obesity or overweight and at least one complication3,417 participants · Total randomized trial population; this row represents the cagrilintide arm | PubMed / New England Journal of MedicinePeer-reviewed publication · June 22, 2025 |
| SurvodutideBI 456906 · GLP-1/glucagon dual agonist | SYNCHRONIZE-1Phase 3 · NCT06066515 · Completed · Weekly injection | 76weeks | 16.6%Comparator: 3.2% mean reduction | Active-arm meanEfficacy estimand, upper reported result | Adults with obesity or overweight726 participants · Actual enrollment in the completed trial record | PubMed / New England Journal of MedicinePeer-reviewed publication · June 7, 2026 |
| RetatrutideLY3437943 · triple agonist · reta | TRIUMPH-1Phase 3 · NCT05929066 · Completed · Weekly injection | 80weeks | 28.3%Comparator: 2.2% mean reduction | Active-arm meanEfficacy estimand | Adults with obesity or overweight and at least one complication2,339 participants · Total randomized master-trial population | Eli Lilly and CompanySponsor topline report · May 21, 2026 |
Full pair evidence
Read the protocol behind commonly confused comparisons.
The builder diagnoses the selected trial rows. These permanent pair guides add mechanism, regulatory status, trial history, direct-versus-separate evidence, and source-by-source interpretation.
How to read the chart
Four fields that change what a percentage means.
- 01
Duration
A 12-week dose-finding signal and an 80-week pivotal result answer different questions. Dividing either result by weeks invents a linear rate the trials did not test.
- 02
Result basis
An active-arm mean is the observed or estimated mean for one group. A placebo-adjusted difference subtracts the comparator. Enicepatide is deliberately labelled differently in the chart.
- 03
Estimand
Efficacy, trial-product, treatment-policy, and treatment-regimen estimands handle adherence, prohibited treatment, and missing outcomes differently. Alternate estimates remain attached to the same record.
- 04
Population and phase
Diabetes status, complications, geography, sample size, dose escalation, and development phase affect interpretation. A small Phase 1 cohort does not carry the same certainty as a large pivotal trial.
Common comparison questions
Resolve the question before comparing the percentage.
Each answer resolves a naming or measurement error before sending the reader to the primary record.
Which experimental weight-loss drug reported the highest mean percentage in this chart?
Retatrutide's TRIUMPH-1 sponsor report lists 28.3% mean weight reduction at 80 weeks for the 12 mg group under an efficacy estimand. That is the highest plotted value in this selected dataset, but it is not proof that retatrutide is better than every other program. The trials used different durations, populations, doses, phases, statistical methods, and comparator responses.
Can I compare Retatrutide, CagriSema, MariTide, and Survodutide percentages directly?
You can compare how each result was reported, but you cannot treat the numerical gap as a head-to-head treatment effect. Retatrutide, CagriSema, MariTide, and Survodutide were randomized in separate protocols with different durations, populations, dose plans, adherence assumptions, missing-data rules, and placebo results.
Is Amycretin now called Zenagamtide?
Yes. Novo Nordisk now uses Zenagamtide for the program formerly called Amycretin. Both oral and injected formulations are in development. The 13.1% result plotted here came from a small 12-week oral Phase 1 cohort with 16 active participants, not from an approved weight-loss pill.
Is Cagrilintide the same as CagriSema?
No. Cagrilintide is a standalone amylin analogue. CagriSema is a fixed-dose combination of cagrilintide and semaglutide. REDEFINE 1 included separate randomized arms, so the combination's 22.7% trial-product estimate cannot be assigned to cagrilintide alone.
Which oral weight-loss drugs are included?
The chart includes the 12-week oral Zenagamtide, formerly Amycretin, Phase 1 cohort and the separate 13-week VK2735 oral Phase 2 trial. Both remain investigational. A short trial signal does not establish an approved tablet, long-term effect, final dose, safety profile, or superiority.
What is the difference between an active-arm mean and a placebo-adjusted result?
An active-arm mean describes the average change observed in an active treatment group. A placebo-adjusted result describes the difference between active treatment and placebo. Those are not interchangeable numbers. Enicepatide's 22.5% plotted value is placebo-adjusted, while most rows show an active-arm mean.
Why can ClinicalTrials.gov enrollment differ from the published participant count?
The registry is a living study record, while a publication or sponsor result may report a particular randomized population, cohort, or analysis set. This tool keeps the current registry enrollment and the outcome source's participant basis in separate fields so the two numbers are not mistaken for the same denominator.
How can I compare two weight-loss drug trial results fairly?
Start with whether the drugs shared randomization. Then compare the result basis, estimand, duration, phase, population, route, masking, and source maturity. The two-drug builder exposes those fields without subtracting percentages from separate trials or converting them into an invented weekly rate.
Open comparison dataReuse the rows.
Reuse the rows.
Keep the caveats.
The HTML landing page, CSV, and JSON distributions share the same 15 source-linked observations. Cite the landing page so definitions, corrections, and evidence limits travel with the numbers.
Primary source ledger
14 direct source routes.
Peer-reviewed publications are preferred when they contain the plotted analysis. Sponsor records are labelled when results have not yet been matched to a full publication.
Sponsor topline reportMariTideAmgen · June 23, 2025↗Sponsor presentationZenagamtideNovo Nordisk · March 2024↗Peer-reviewed publicationCagriSemaPubMed / New England Journal of Medicine · June 22, 2025↗Peer-reviewed publicationCagrilintidePubMed / New England Journal of Medicine · June 22, 2025↗Sponsor topline reportRetatrutideEli Lilly and Company · May 21, 2026↗Peer-reviewed publicationMazdutideNew England Journal of Medicine · May 28, 2025↗Peer-reviewed publicationMazdutidePubMed / JAMA · June 8, 2026↗Sponsor topline reportEnicepatideRoche · January 27, 2026↗Peer-reviewed publicationEloralintidePubMed / The Lancet · November 7, 2025↗Sponsor topline reportPetrelintideRoche · March 5, 2026↗Peer-reviewed publicationSurvodutidePubMed / New England Journal of Medicine · June 7, 2026↗Peer-reviewed publicationVK2735 injectionPubMed / Obesity · January 8, 2026↗Sponsor topline reportVK2735 oralViking Therapeutics · May 12, 2026↗Sponsor topline reportEcnoglutideSciwind Biosciences · March 6, 2026↗Sponsor topline reportPemvidutideAltimmune · June 23, 2024↗
Evidence checked July 21, 2026. Trial and regulatory records can change after publication.